In8Bioincis A Clinical Stage Biopharmaceutical Company Founded In 2016Based In New York Citywith Scientific Operations In Birminghamalabamathe Company Is Dedicated To Developing Innovative Therapies For Cancerfocusing On Gamma Delta T Cell Therapiesthese Unconventional T Cells Have Unique Properties That Make Them Promising For Treating Various Cancers In8Bio S Product Pipeline Includes Several Therapiessuch As Inb 200 For Glioblastomainb 300 For Ovarian Cancerand Inb 400 For Other Solid Tumorsthe Company Is Also Advancing Gamma Delta T Cell Engagers Like Inb 619Which Targets Cd19 And Has Shown Encouraging Results In Preclinical Studiescurrentlyin8Bio Is Conducting Phase 1 2 Clinical Trials For Its Lead Candidatesdemonstrating Potential For Long Term Remissions In Challenging Cancer Cases The Company Collaborates With Renowned Institutionsincluding Memorial Sloan Kettering Cancer Center And Md Anderson Cancer Centerto Enhance Its Research And Clinical Effortsin8Bio Is Publicly Traded On The Nasdaq Under The Ticker Symbol Inab
| Company Name | In8bio Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
